Voltage-Gated Ion Channels in Neuropathic Pain Signaling DOI Creative Commons
Ricardo Felix, Alejandra Corzo-López, Alejandro Sandoval

и другие.

Life, Год журнала: 2025, Номер 15(6), С. 888 - 888

Опубликована: Май 30, 2025

Neuropathic pain is a chronic and debilitating disorder of the somatosensory system that affects significant proportion population characterized by abnormal responses such as hyperalgesia allodynia. Voltage-gated ion channels, including sodium (NaV), calcium (CaV), potassium (KV) play pivotal role in modulating neuronal excitability signal transmission following nerve injury. This review intends to provide comprehensive analysis molecular cellular mechanisms which dysregulation expression, localization, function specific NaV channel subtypes (mainly NaV1.7 NaV1.8) their auxiliary subunits contributes aberrant activation, generation ectopic discharges, sensitization neuropathic pain. Likewise, special emphasis placed on crucial CaV particularly CaV2.2 subunit CaVα2δ, whose overexpression increases influx, neurotransmitter release, hyperexcitability, thus maintaining persistent states. Furthermore, KV channels (particularly KV7 channels) brakes excitability, facilitates development maintenance Therefore, targeting restore also promising therapeutic strategy for alleviating symptoms. On other hand, recent advances small molecules selective modulators or inhibitors voltage-gated are discussed. These agents have improved efficacy safety profiles preclinical clinical studies attenuating pathophysiological activity restoring function. seeks contribute guiding future research drug toward more effective mechanism-based treatments discussing underlying highlighting translational opportunities.

Язык: Английский

Differential state-dependent Nav1.8 inhibition by suzetrigine, LTGO-33, and A-887826 DOI
Sooyeon Jo, Akie Fujita, Tomás Osorno

и другие.

The Journal of General Physiology, Год журнала: 2025, Номер 157(4)

Опубликована: Март 26, 2025

Nav1.8 sodium channels are expressed in pain-sensing neurons, and some inhibitors significantly reduce pain clinical trials. Several have an unusual state dependence whereby inhibition is relieved by depolarization. We compared the state-dependent action of several channel to test whether during potential (AP) firing under physiological conditions produce “reverse use dependence.” A-887826 was substantially AP waveforms applied at 20 Hz 37°C. In contrast, there no relief trains with suzetrigine (VX-548) or LTGO-33, even though could be effectively removed long, strong depolarizations. These differences were explained voltage kinetics which compounds dissociate from depolarized rebind resting channels. Suzetrigine required strongest depolarizations for (midpoint +33 mV) slow (tau >300 ms +20 mV), so almost occurred waveform. Relief weaker +13 much faster, each waveform accumulated 20-Hz trains. LTGO-33 weakest −11 faster than A-887826, but reinhibition between far that did not accumulate Hz. The results show that, unlike use-dependent temperatures, different reasons.

Язык: Английский

Процитировано

2

New approaches to opioid-free pain treatment DOI

Mike May

Nature Medicine, Год журнала: 2025, Номер unknown

Опубликована: Апрель 10, 2025

Язык: Английский

Процитировано

1

US drug agency approves potent painkiller — the first non-opioid in decades DOI

Elie Dolgin

Nature, Год журнала: 2025, Номер unknown

Опубликована: Янв. 31, 2025

Язык: Английский

Процитировано

1

Sensory neuron sodium channels as pain targets; from cocaine to Journavx (VX-548, suzetrigine) DOI
John N. Wood, Nieng Yan, Jian Huang

и другие.

The Journal of General Physiology, Год журнала: 2025, Номер 157(4)

Опубликована: Апрель 28, 2025

Voltage-gated sodium channels underpin electrical signaling in sensory neurons. Their activity is an essential element the vast majority of pain conditions, making them significant drug targets. Sensory neuron play roles not only afferent but also a range efferent regulatory mechanisms. Side effects through actions on other cell types and are thus important issues to address during analgesic development. As example, human genetic evidence for NaV1.7 as ideal target contrasts with side antagonists. In this review, we describe history progress toward development useful drugs renewed focus NaV1.8 key treatment. antagonists alone or combination analgesics likely provide new opportunities relief number people (about 33% population) impacted by chronic pain, particularly present aging populations.

Язык: Английский

Процитировано

0

From a clinically relevant pain target to a possible analgesic treatment strategy DOI Creative Commons
Alban Latrémolière

Neurotherapeutics, Год журнала: 2025, Номер unknown, С. e00542 - e00542

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0

Dezocine and Addiction: Friend or Foe? DOI Creative Commons
Wayne E. Childers, Khaled M. Elokely, Magid Abou‐Gharbia

и другие.

Pharmaceuticals, Год журнала: 2025, Номер 18(3), С. 386 - 386

Опубликована: Март 8, 2025

The neurological effects of opium were first described over 8000 years ago. Morphine was isolated in 1803 and by the mid-1800s had become both a pain-relieving blessing an addictive curse. As part crusade to identify safer more reliable alternatives morphine, dezocine (Dalgan®) marketed US 1986. Its use discontinued 2011 without revealing reasons, but it remains one most widely used analgesic agents China today. Dezocine’s unique pharmacology makes effective with limited opioid-associated side little or no reported potential for dependence addiction. In addition, dezocine’s blocking effect on serotonin norepinephrine transporters recommends its further exploration as treatment various chronic neuropathic pain conditions. Most recently, data suggest that might represent viable addiction management. This report focuses supporting non-addictive profile treat opioid withdrawal, well recent efforts generate formulations support sub-chronic dosing.

Язык: Английский

Процитировано

0

Medicine vs. Myth: Exploring the Therapeutic Potential of Cannabis for Opioid Use Disorder and Pain DOI
Pooja R. Sarkar,

Charlene D. Vincent,

Anthony Szeto

и другие.

Current Addiction Reports, Год журнала: 2025, Номер 12(1)

Опубликована: Март 18, 2025

Язык: Английский

Процитировано

0

Suzetrigine for moderate to severe acute pain DOI
Eun Bee Cho,

Chenyao Jiang,

Zihan Wang

и другие.

Trends in Pharmacological Sciences, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Процитировано

0

Spinal neuron-glial crosstalk and ion channel dysregulation in diabetic neuropathic pain DOI Creative Commons
Jie Wu,

Haijun Hu,

Xi Li

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Апрель 8, 2025

Diabetic neuropathic pain (DNP) is one of the most prevalent complications diabetes, characterized by a high global prevalence and substantial affected population with limited effective therapeutic options. Although DNP closely associated hyperglycemia, an increasing body research suggests that elevated blood glucose levels are not sole inducers DNP. The pathogenesis intricate, involving release inflammatory mediators, alterations in synaptic plasticity, demyelination nerve fibers, ectopic impulse generation, yet precise mechanisms remain to be elucidated. spinal dorsal horn coordinates dynamic interactions between peripheral central pathways, wherein neurons, microglia, astrocytes synergize Schwann cell-derived signals process nociceptive information flow. Abnormally activated neurons can alter signal transduction modifying local microenvironment, compromising myelin integrity, diminishing trophic support, leading neuronal sensitization amplifying effect on signals, which turn triggers pain. Ion channels play pivotal role conduction, modulation sodium, potassium, calcium being particularly crucial for regulation signals. In light rising incidence diabetes current scarcity treatments, thorough investigation into glial cells, especially ion channel function DNP, imperative identifying potential drug targets, developing novel strategies, thereby enhancing prospects management.

Язык: Английский

Процитировано

0

The Persistent Pain Enigma: Molecular Drivers Behind Acute-to-Chronic Transition DOI
Abdul Nasır,

Maryam Afridi,

Ome Kalsoom Afridi

и другие.

Neuroscience & Biobehavioral Reviews, Год журнала: 2025, Номер 173, С. 106162 - 106162

Опубликована: Апрель 14, 2025

Язык: Английский

Процитировано

0